/ /

  • linkedin
  • Increase Font
  • Sharebar

    What does 2017 have in store for ophthalmology?

     

    What are you looking forward to in 2017?

    Dr. Masket: Perhaps not in 2017, but soon enough I am anticipating improved IOL designs with regard to accommodation and reduced incidence of undesirable side effects, including the dysphotopsias.

    Dr. Snyder: The FDA study on the custom-matched, flexible artificial iris has completed enrollment of its PMA arm. I am hopeful that 2017 will usher in a PMA approval for this special device. [Disclosure: I am medical monitor for the study and a consultant for Humanoptics, the manufacturer of the device.]

    Dr. Fekrat: Recently, the FDA approved prefilled ranibizumab (Lucentis, Genentech) syringes. Watson Health cognitive imaging tool for ophthalmology.

    Dr. Maloney: I am hoping for FDA approval of the Light Adjustable IOL.

    Dr. Hoffman: I am looking forward to future advancements in IOL technology including trifocal IOLs and increasing utilization of increased depth-of-focus IOLs.

    Dr. Lee: Argus II

    Dr. Kornmehl: Femto cataract surgery will continue to gain in popularity and will soon be the standard of care in some communities. Ophthalmic imaging will continue to play and expanding role in ophthalmology, particularly corneal surgery. Anterior segment OCT will be crucial in performing inlays in patient who have already had LASIK and PRK. We will soon have technology to measure the central cornea directly and distorted corneas, which will revolutionize our ability to determine implant powers in post refractive surgery patients and quickly fit patients with scleral lenses.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results